Showing results (471-480 of 528) with videos related to
Sort By:
Pageof 53
Biorxiv : the Preprint Server for Biology|June 9, 2020
Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike proteinAnna Z Wec, Daniel Wrapp, Andrew S Herbert, et al.SSRN|August 4, 2020
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular ProbesTongqing Zhou, I-Ting Teng, Adam S Olia, et al.The New England Journal of Medicine|July 15, 2020
An mRNA Vaccine against SARS-CoV-2 - Preliminary ReportLisa A Jackson, Evan J Anderson, Nadine G Rouphael, et al.Science (New York, N.Y.)|January 30, 2025
Pre-exposure antibody prophylaxis protects macaques from severe influenzaMasaru Kanekiyo, Rebecca A Gillespie, Kristine Cooper, et al.Science Translational Medicine|December 25, 2015
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infectionRebecca M Lynch, Eli Boritz, Emily E Coates, et al.Biorxiv : the Preprint Server for Biology|June 30, 2020
Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular ProbesTongqing Zhou, I-Ting Teng, Adam S Olia, et al.The New England Journal of Medicine|September 29, 2020
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsEvan J Anderson, Nadine G Rouphael, Alicia T Widge, et al.The Lancet. HIV|September 2, 2019
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trialMartin R Gaudinski, Katherine V Houser, Nicole A Doria-Rose, et al.The Lancet. HIV|April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trialTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.Annals of the New York Academy of Sciences|April 6, 2023
Progress in vaccine development for infectious diseases-a Keystone Symposia reportJennifer Cable, Barney S Graham, Richard A Koup, et al.Pageof 53